Recapping Friday’s Interests
Friday’s session bore some nice opportunities among the plays we were discussing in our premarket report, from both options and stocks.
Our top options target turned out to be Expedia, Inc. EXPE, in which we were tracking the Weekly $115-117 Calls. Every one of the contracts in that range produced chances for multi-bag gains:
$115 Calls – Daily Range: 1.12-5.04 – Max Gain: 350%
$116 Calls – Daily Range: 1.32-6.40 – Max Gain: 385%
$117 Calls – Daily Range: .87-4.12 – Max Gain: 374%
___
On the stock side of things, we were observing Hutchinson Technology, Inc. HTCH which had caught our eye on a routine premarket scan for abnormal activity. The stock responded with a solid session to close out the week, trading from a low of 1.60, and reaching as high as 1.95; a respectable 22% intraday move.
___
We also wanted to say a quick word about Wizard World, Inc. WIZD, which we called as a potential bottom-play after noticing the stock tumbling to new 52-wk lows. The stock managed to make a nominal 18% intraday jump off of that bottom, so we’ll watch for the possibility of a protracted recovery. We’ll look for WIZD to continue to register higher lows.
Mobile Broadcasting Holding, Inc. MBHC
MBHC responded well to Friday’s news regarding the findings of beta testing on its upcoming app (View PR), as it continued to build a higher base of support off of the .0042 swing-low that it recorded last Tuesday.
We watched the stock trade in a range from .0052 to .006 (+15%), and that high marked an overall four-session move of 43% It drew back slightly to close at .0057, the point from which we’ll look to see it continue to log higher lows as we commence a new trading week.
We’ve prepared a video highlighting the key points of the MBHC chart:
Fresh News Plays
Lexicon Pharmaceuticals, Inc. LXRX is gapping up heavily this morning after the company published an early-morning PR announcing that its Phase III cancer treatment has met primary endpoints. We can look for short-term opportunities in the stock itself, and in the options chain, where we’ll monitor $10 Calls. Be on the lookout for a possible dip-and-rip scenario!
Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome (Mon 1:01AM EDT)
Mixx 1 Life, Inc. MIXX is also piquing our interest with a premarket PR and its positioning on the chart as a good bottom-watch candidate The stock has fallen dramatically to new 52-week lows, and is looking extremely oversold. The CEO has released a letter to shareholders today addressing the extreme conditions, and we’re going to slate this one for observation as the potential recovery could produce some serious chances for profit.
- CEO and President of Mix1 Life Addresses Share Price and Has Commenced Action Against Seeking Potential Short Seller (Mon 8:00AM EDT)